Available for full-service programs and stand-alone projects for both large and small molecules for all phases of the drug development lifecycle.
Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today welcomed the recent announcement by Nectero Medical that they have received clearance from the U.S. Food and Drug Administration of their IND application to initiate Phase II/III trial of the Nectero Endovascular Aneurysm Stabilization Treatment (EAST®) System for the treatment of small- to-mid-sized abdominal aortic aneurysms (AAA).
Years of Experience
Investigational New Drug Filing
Molecules Supported Annually
Looking to explore new career opportunities?
Alcami offers a supportive team environment and remarkable scientific expertise to grow your career.
Free Healthcare | Bonus Program | 401(k) with Match | College Loan Forgiveness
If you are looking for a fulfilling workplace, you have come to the right company. Our employees are our biggest resource.